91-105 of 831
Evaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease
NeuroFrontiersEvaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease
Sharon Sha, MD, MS
Real-World Cases in Pediatric Low-Grade Glioma: Exploring Targeted Therapies
Project Oncology®Real-World Cases in Pediatric Low-Grade Glioma: Exploring Targeted Therapies
Alexandria May, PharmD, BCPS
Angela Waanders, MD, MPH, MS
Ashley S. Margol, MD, MS
Evaluating Sabirnetug in Early Alzheimer’s: Targeting Soluble Aβ Oligomers
NeuroFrontiersEvaluating Sabirnetug in Early Alzheimer’s: Targeting Soluble Aβ Oligomers
Individualized Cognitive Stimulation in Mild Alzheimer’s Disease: Evidence from a Multicenter RCT
NeuroFrontiersIndividualized Cognitive Stimulation in Mild Alzheimer’s Disease: Evidence from a Multicenter RCT
Aducanumab in Early Alzheimer's: Slowing Cognitive and Functional Decline
NeuroFrontiersAducanumab in Early Alzheimer's: Slowing Cognitive and Functional Decline
Ryan Quigley
Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices
NeuroFrontiersOptimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices
Sheetal Shroff, MD
- advertisement
Timing Meningococcal Vaccines in gMG: Challenges and Considerations
NeuroFrontiersTiming Meningococcal Vaccines in gMG: Challenges and Considerations
Michael Weiss, MD
Individualizing gMG Treatment: Defining Success With Each Patient
NeuroFrontiersIndividualizing gMG Treatment: Defining Success With Each Patient
Omar Sinno, MD
Linking Obesity to Alzheimer’s: The Lipid Signals Driving Neurodegeneration
Clinician's RoundtableLinking Obesity to Alzheimer’s: The Lipid Signals Driving Neurodegeneration
Stephen Wong, PhD
LUMINESCE: Assessing Satralizumab in Generalized Myasthenia Gravis
NeuroFrontiersLUMINESCE: Assessing Satralizumab in Generalized Myasthenia Gravis
Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
NeuroFrontiersAdvancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
Examining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT
NeuroFrontiersExamining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT
Ryan Quigley
- advertisement
Advancing MS Care: Diagnostic Clarity, Early Action, and Patient-Centered Treatment
On the Frontlines of Multiple SclerosisAdvancing MS Care: Diagnostic Clarity, Early Action, and Patient-Centered Treatment
Tirisham V. Gyang, MD
Gates B. Colbert, MD
Prevention on the Horizon: Early Intervention and Risk Reduction in MS Care
On the Frontlines of Multiple SclerosisPrevention on the Horizon: Early Intervention and Risk Reduction in MS Care
Vikram V. Bhise, MD
Evolving Diagnostic and Prognostic Strategies in Multiple Sclerosis Care
On the Frontlines of Multiple SclerosisEvolving Diagnostic and Prognostic Strategies in Multiple Sclerosis Care
Ashley Baker, MSN, PMHNP
Jay Avasarala, MD, PhD
